
### [MONDO:0015816](http://purl.obolibrary.org/obo/MONDO_0015816)
**Label:** indolent primary cutaneous T-cell lymphoma

**Subclasses:** [MONDO:0018897](http://purl.obolibrary.org/obo/MONDO_0018897) (primary cutaneous CD30+ T-cell lymphoproliferative disease), [MONDO:0009691](http://purl.obolibrary.org/obo/MONDO_0009691) (mycosis fungoides), [MONDO:0015808](http://purl.obolibrary.org/obo/MONDO_0015808) (Folliculotropic mycosis fungoides), [MONDO:0017598](http://purl.obolibrary.org/obo/MONDO_0017598) (primary cutaneous anaplastic large cell lymphoma), [MONDO:0015809](http://purl.obolibrary.org/obo/MONDO_0015809) (localized pagetoid reticulosis), [MONDO:0019475](http://purl.obolibrary.org/obo/MONDO_0019475) (subcutaneous panniculitis-like T-cell lymphoma), [MONDO:0018031](http://purl.obolibrary.org/obo/MONDO_0018031) (granulomatous slack skin), [MONDO:0015810](http://purl.obolibrary.org/obo/MONDO_0015810) (primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma), [MONDO:0015821](http://purl.obolibrary.org/obo/MONDO_0015821) (mycosis fungoides and variants), [MONDO:0020326](http://purl.obolibrary.org/obo/MONDO_0020326) (lymphomatoid papulosis), 

**Corr. equiv. classes:** [Orphanet:178512](http://www.orpha.net/ORDO/Orphanet_178512), [Orphanet:541](http://www.orpha.net/ORDO/Orphanet_541), [Orphanet:300865](http://www.orpha.net/ORDO/Orphanet_300865), [Orphanet:178517](http://www.orpha.net/ORDO/Orphanet_178517), [Orphanet:33111](http://www.orpha.net/ORDO/Orphanet_33111), [Orphanet:2584](http://www.orpha.net/ORDO/Orphanet_2584), [OMIM:254400](http://purl.obolibrary.org/obo/OMIM_254400), [Orphanet:178522](http://www.orpha.net/ORDO/Orphanet_178522), [Orphanet:178566](http://www.orpha.net/ORDO/Orphanet_178566), [Orphanet:86884](http://www.orpha.net/ORDO/Orphanet_86884), [Orphanet:98842](http://www.orpha.net/ORDO/Orphanet_98842), 

**Class expressions from DL-Learner:**

- [HP:0002665](http://purl.obolibrary.org/obo/HP_0002665) (Lymphoma) and [HP:0010783](http://purl.obolibrary.org/obo/HP_0010783) (Erythema) and [HP:0100763](http://purl.obolibrary.org/obo/HP_0100763) (Abnormality of the lymphatic system) 56.94%
- [HP:0002665](http://purl.obolibrary.org/obo/HP_0002665) (Lymphoma) and [HP:0002733](http://purl.obolibrary.org/obo/HP_0002733) (Abnormality of the lymph nodes) and [HP:0010783](http://purl.obolibrary.org/obo/HP_0010783) (Erythema) 56.94%
- [HP:0002665](http://purl.obolibrary.org/obo/HP_0002665) (Lymphoma) and [HP:0010783](http://purl.obolibrary.org/obo/HP_0010783) (Erythema) 44.25%
- [HP:0002665](http://purl.obolibrary.org/obo/HP_0002665) (Lymphoma) and [HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system) and [HP:0010783](http://purl.obolibrary.org/obo/HP_0010783) (Erythema) 44.25%
- [HP:0002665](http://purl.obolibrary.org/obo/HP_0002665) (Lymphoma) and [HP:0011276](http://purl.obolibrary.org/obo/HP_0011276) (Vascular skin abnormality) 33.50%
- [HP:0002665](http://purl.obolibrary.org/obo/HP_0002665) (Lymphoma) 23.99%
- [HP:0002733](http://purl.obolibrary.org/obo/HP_0002733) (Abnormality of the lymph nodes) 20.53%
- [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) 20.34%
- [HP:0011276](http://purl.obolibrary.org/obo/HP_0011276) (Vascular skin abnormality) 17.53%
- [HP:0100763](http://purl.obolibrary.org/obo/HP_0100763) (Abnormality of the lymphatic system) 17.23%
- [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 16.57%
- [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) 16.43%
- [HP:0001871](http://purl.obolibrary.org/obo/HP_0001871) (Abnormality of blood and blood-forming tissues) 15.90%
- [HP:0002597](http://purl.obolibrary.org/obo/HP_0002597) (Abnormality of the vasculature) 15.90%
- [HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system) 15.62%


